Clinical Report: Dexamethasone may reduce severe ROP

Overview

Topical dexamethasone eye drops may reduce the progression to treatment-requiring retinopathy of prematurity (ROP) in extremely preterm infants, although the primary endpoint was not met in a randomized clinical trial. The trial showed a 47% relative risk reduction in treatment-requiring ROP, but this difference did not reach statistical significance.

Background

Retinopathy of prematurity is a significant cause of visual impairment in preterm infants, necessitating effective preventive strategies. The use of topical dexamethasone has been explored as a potential intervention to reduce the need for invasive treatments in this vulnerable population. Understanding the efficacy and safety of such treatments is crucial for improving outcomes in extremely preterm infants.

Data Highlights

Key Findings

• 20% of infants receiving dexamethasone progressed to treatment-requiring ROP compared to 38% in the placebo group.
• This represents a 47% relative risk reduction, although not statistically significant.
• In the per-protocol analysis, 19% of infants receiving dexamethasone progressed compared to 39% of those receiving placebo.
• No significant differences were observed in time to progression or recurrence following treatment between groups.
• Adverse events were similar between the dexamethasone and placebo groups, with no clinically significant difference in intraocular pressure.
• Exploratory analyses suggested greater benefits in infants with birth weights greater than 660 g.

Clinical Implications

The findings indicate that topical dexamethasone may reduce the need for invasive treatment in ROP, but the lack of statistical significance suggests caution in clinical application.

Conclusion

Topical dexamethasone may reduce the need for invasive treatment for ROP in extremely preterm infants, but further studies are needed to validate these findings.

Related Resources & Content

1. Hellström A, JAMA Pediatrics, 2023 -- Dexamethasone may reduce severe ROP
2. retinal physician — Dexamethasone Intravitreal Implant Following RVO: Rescue, Adjunct or Primary Therapy?
3. Retinal Physician — Dexamethasone Intracameral Drug-delivery Suspension for Inflammation Following Vitreoretinal Surgery
4. the ophthalmologist — A Sequential Approach to DME
5. retinal physician — Dexamethasone Intracameral Drug-delivery Suspension for Inflammation Following Vitreoretinal Surgery
6. Screening Examination of Premature Infants for Retinopathy of Prematurity
7. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW)
8. Treating Retinopathy of Prematurity with Dexamethasone Eye Drops - Ophthalmology